Erbitux gains expanded approval in Europe

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

Cetuximab (Erbitux) has received broader approval in the European Union as a first-line treatment for metastatic colorectal cancer.

Cetuximab (Erbitux) has received broader approval in the European Union as a first-line treatment for metastatic colorectal cancer. Erbitux can now be used in European patients with EGFR-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy and also as a single agent in patients who have failed oxaliplatin (Eloxatin)-based and irinotecan (Camptosar)-based therapy, according to manufacturer Merck KGaA of Darmstadt, Germany.

European Commission approval was based on data from two randomized, controlled trials. In the phase III CRYSTAL study, patients with KRAS wild-type tumors had a 59% response rate with cetuximab/chemotherapy vs 43% for chemotherapy alone. In the phase II OPUS trial, response rates were 61% vs 37%, respectively.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.